Review Article
Risk of Parkinson’s Disease in the Users of Antihypertensive Agents: An Evidence from the Meta-Analysis of Observational Studies
Table 6
Overall effect estimates for Parkinson’s disease and Angiotensin converting enzyme inhibitors use according to subgroups.
| | Characteristics | Number of studies | RR (95% CI) | value | Cochrane value | value |
| | All studies | 3 | 0.98 (0.77–1.2) | 0.01 | 0.023 | 73.422 |
| | Study design | | | | | | | Cohort | 1 | 0.80 (0.64–0.96) | 0.12 | 0.840 | 0.000 | | Case-control | 2 | 1.09 (0.64–1.24) | 0.14 | 1.000 | 0.000 |
| | Gender | | | | | | | Men | 1 | 0.88 (0.63–1.23) | NA | NA | NA | | Women | 2 | 0.76 (0.56–1.05) | 0.00 | 0.954 | 0.000 |
| | Quality | | | | | | | High | 1 | 0.80 (0.69–1.01) | NA | NA | NA | | Medium | 2 | 1.09 (0.95–1.24) | 0.00 | 0.840 | 0.000 |
|
|
NA: not available.
|
